Several actin-binding proteins have been shown to be altered in metastat ic cell lines and tumours and, in particular, Myristoylated Alanine-Rich protein Kinase C substrate (MARCKS) has been implicated in the pathogenesi s of various highly metastatic epithelial malignancies. Considerin g that a large percentage of deaths due to colorectal cancer (CRC) are consequent to hepatic metastasization, aim of this study was to elucidate the involvement and mechanism of MARCKS in CRC by employing in vitro and in vivo approache s. Loss-of and-gain-on function approaches of MARCKS were employed in two human CRC cell lines: Clone A cells expressing MARCKS and LoVo cells known to have a frameshift mutation of MARCKS i.e. typically for MSI-H CRC. The data unveiled that altering MARCKS expression suppresses cell motility and invasion in human colon carcinoma cells when conditioned medium of liver-specific stromal cells (hepatic stellate cells) was used as chemoattractant. Depletion or re-expression of MAR CKS inhibited proliferati on with a reduction in expression of the mitotic regulator Aurora B kinase (AURKB), whereas AURKB -depletion did not modify MARCKS expression. In murine colon carcinoma CT26 cells, shRNA MARCKS-d epletion reduced motility and invasion, and induced an aberrant, prolonged mitotic process. Significantly less metastases were produced in a syngenei c model of colon metastasis by MARCKSdepleted CT26 in comparison to CT26-tumour challenged mice. In conclusion, MAR CKS plays an articulated role in the progression of colorectal cancer and might represent a suitable target to interfere and overcome the invasive behaviour of colon carcinoma cells at primary and distant sites.
Introduction
Tumour growth and progression is not entirely due to genetic aberrations but also reflective of tumour cell plasticity. To metastasize, tumour cells must achieve a higher cell membrane plasticity and motion which are largely driven by the actin cytoskeleton and relies on the actin-based cytoskeleton reorganizati on [1] . Actin is the major constituent of the microfilament system and shows a high degree of structural plasticity. This plasticity is provided by the interplay between the monomeric , oligomeri c and polymeric forms of actin and specializ ed actin-binding proteins that control the polymerisation and de-polymer isation of actin [2] . Several of these actin-binding proteins are up-or down-regulated in metastatic cell lines and tumours. In particular , recent studies have identified Myristoylat ed Alanine-Ric h C Kinase Substrate (MARCKS) to be implicate d in the pathogenesis of various malignancies such as pituitary and thyroid cancer [3] , breast cancer [4] , melanoma [5] , glioblastoma multiform e cancer [6, 7] , and cholangiocarci noma [8] .
Overall, the function of MARCKS in these malignancies seems to be multiface ted and depends on cell type and tumour origin. The identification of MARCKS as a frequent target of mutation in colorectal carcinomas and small intestinal adenocarci nomas with MSI-H [9] [10] [11] certainly adds more complexity to the involvement of MARCKS in tumour formatio n. Indeed, the observed mutation in the effector domain of MARCKS, which contains the actin bindings domains, [12, 13] may lead to an aberrant re-organization of the actin cytoskeleton affecting processes such as motility, invasion and prolifera tion. A defect in the actin cytoskeleton architecture could then be associated with an aberrant cell cycle. Indeed, an aberrant regulation or localization of the mitotic regulator AURKB has been linked to genomic instability, tumourigenes is, tumour progression , and poor prognosis in a wide variety of cancer types including CRC [14] [15] [16] . Along these lines, we have previously demonstrated a close interaction between MARCKS and AURKB during mitosis. In particular, the specific cellular distribut ion of AURKB during the different mitotic steps depends on the presence of MARCKS and MARCKS regulation of actin filament formation [17] .
Overall, the functional role of MARCKS during colorectal tumour progression and metastasizatio n is largely unknown. Therefore, the aim of the present study was to investiga te the functiona l role of MARCKS in vitro , by performi ng gain-on and-of experiments in CRC cell lines and in vivo by using a syngeneic murine model of liver metastasis.
Materials and methods

Reagents
Antibodies against alpha-smooth muscle actin (a-SMA) (mouse ascites, clone 1A4), b-actin (AC-15) and anti-actin (rabbit, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and all reagents used in this study are from Sigma Aldrich (Saint Louis, MI) or otherwise mentioned. Antibodies against AURKB (AIM-1) were purchased from Sigma (rabbit, A5102) or BD Transduction Laboratories (mouse, AIM-1). Primary antibodies against MARCKS (N-19 and M20), P-MARCKS (Ser159/163), a-tubulin (H-300) were purchased from Santa Cruz Biotechnology as well as their secondary antibodies, respectively HRP-conjugated goat or rabbit IgG. All antibodies were used according to the manufacturer's manual.
Cells and cell culture
All cell lines were obtained from American Type Culture Collection (Manassas, VA) and were cultured in RPMI completed with 2 mM/L glutamine, 1.0 mM/L sodium pyruvate and supplemented with 10% Foetal Bovine Serum (FBS) (all provided by GIBCO Laboratories, NY). Human hepatic stellate cells (hHSCs) were isolated from wedge sections of normal human liver unsuitable for transplantation, as extensively described elsewhere [18] . Cells were cultured in Iscove's Modified DMEM supplemented with 0.6 U/ml insulin, 2 mM/L glutamine, 0.1 mM/L nonessential amino acids, 1.0 mM/L sodium pyruvate and 20% FBS. Harvesting the conditioned medium of hHSC (hHSC-CM) was performed at passage 5. At these stage, cells show functional and ultrastructural features of fully activated HSC [19] . Mice (mHSC) were isolated from liver Balb/c mice followed by density gradient centrifugation and culturing conditions as mentioned before. Conditioned medium of activated hHSC-CM and mHSC (mHSC-CM) was harvested after 48 h of incubation in serum-free medium. All cell lines were cultured under standard conditions in a humidified incubator under 5% CO 2 in air at 37 °C.
Conditioned medium from human or murine HSC was employed as a specific stimulus for CRC cell migration and invasion assays. This choice was based on previous published evidence indicating that activated HSC produce and secrete soluble factors and chemokines that promote a pro-inflammatory microenvironment, tissue angiogenesis and tumour progression. Therefore, activated hHSC favour the ''homing'' of tumour cells in the liver microenvironment [20] [21] [22] . Hence, the conditioned medium of activated hHSC is as an excellent and specific tool to investigate the possible cross-talk between cancer cells and hHSC during chemotaxis.
Protein extraction, immunoprecipitation and Western blot analysis
For immunoblot analysis whole cell lysates were separated on SDS-PAGE, transferred to nitrocellulose, and immunoblotted as described previously [23] . An antibody against a-SMA, total actin, a-tubulin or PCNA was used to demonstrate equal loading. 30 nM AURKB siRNA or 50 nM MARCKS SiRNA was mixed with 5 ll of siLentFect™ and added to the cells. Scrambled control siRNA was used in every transfection experiment [23] .
Stable gene silencing : Murine colon carcinoma CT26 cells were stable transfected with murine validated short Hairpin RNA (TR512267, 4 shRNA constructs with puromycin cassette, containing two control shRNA) (OriGene Technologies, MD). Briefly, 3 Â 10 5 cells were cultured in a 6-well plate and after 24 h cells were transfected with 1 lg/3 ml of shRNA construct using the Mirus 2300 Trans-IT-LT1 transfection reagent (Mirus Bio LLC, WI) and 8 ll/ml of puromycin was added to the medium. Single cell colonies were selected and experiments were performed on single cell colonies of the 4th generation. MARCKS plasmid transient transfection assay : LoVo cells were transiently transfected with a human MARCKS plasmid (WT-PJ7) or empty vector using the Lipofect-AMINE reagent (Life Technologies, Invitrogen). Furthermore, two different MARCKS cDNA mutations were investigated: (1) a myristoylated mutant (PJ7-G1A, Myr-m) where the N-terminal glycine was replaced by an alanine that is unable to insert MARCKS protein into the plasma membrane but still contains the functional domain, and (2) a deletion mutant of the PSD (PJ7-PSD, PSD-m) which is replaced by Proline-Glycine. All plasmids were kindly given by Dr. S. Manenti (INSERM, Toulouse Cedex, France) [5, 24] . Functional experiments were performed 48 h after each transfection and the transfection efficiency was evaluated by employing proteinand RNA analysis.
Boyden chamber assays
Briefly, Boyden chambers were equipped with 8-lm pore filters Poretics (Livermore, CA) and coated with rattail collagen (Collaborative Biomedical Products, MA) or Matrigel as previously described [20, 23] . After employing gain-on or gain-of studies against MARCKS, cells were trypsinized and re-suspended in serum-free medium at a concentration of 6 Â 10 4 cells/200 ll and added to the upper Boyden chamber. The conditioned medium of human HSC (hHSC-CM) or mouse HSC (mHSC-CM) was used as chemoattractant depending on the cell line species under investigation. After overnight incubation, the cells migrating to the underside of the filters were fixed, stained with Giemsa, mounted and viewed at 40 Â magnification. Data are the average of cell counts obtained in 10 randomly chosen high-power fields (HPF).
RNA isolation and QRT-PCR
Total RNA was isolated with NucleoSpin RNAII (Macherey Nagel) according to the manufacturer's manual and 0.4 lg aliquots were reverse-transcribed with random primers using a Reverse Aid M-MuLV reverse transcription kit (Fermentas). Target cDNA levels were quantified by SYBRE green-based RT-PCR using specific Taqman gene expression-assays (Applied Biosystems) with supplied probes on a Rotor Gene 6000 (Corbett Research).
Expression data from three male patients with colon rectal cancer and paired tissue classified in Stage I (T2, N0, MX), and two patients classified in Stage IV (TX, NX, M1) was generated from total RNAs obtained from OriGene Technologies (CR561166-CR561168, CR56277-CR562676, CR562687-CR562700, CR559462-CR563007, CR560798-CR560801). Additional sample information and pathology reports are available on Origene Technologies website. Measured mRNA levels were normalized to those of b-actin or GAPDH as internal control and performed in triplicate. The relative levels of RNA were determined using the efficiency-corrected threshold cycle (DCT) method.
In vivo liver metastasis assay
Experimental protocols were conducted according to established international guidelines and with the approval of the National Regulatory Authorities and institutional guidelines. Six week old BALB/c mice (20 g, Charles River Laboratories, Italy) were tumour-challenged employing an intrasplenic bolus injection of scrambled control CT26 cells or MARCKS shRNA-depleted CT26 cells (5 Â 10 4 /50 ll PBS1X). Sham-operated mice were obtained by performing the same surgical operation and injected with vehicle. Each group contained five animals. As was empirically proven, all CT26-tumour challenged mice developed liver metastasis. Mice were sacrificed after 23 days. Liver tissue was taken, snap-frozen or fixed in 10% buffered formaldehyde and embedded overnight in paraffin. This was followed by a standard haematoxylin-eosin staining as described previously [17] .
Cell proliferation assays
MTT assay : scrambled control cells and shRNA MARCKS-depleted CT26 cells were seeded into a 12-well culture plate at 4 Â 10 4 cells per well, performed in 6-fold for each condition. Proliferation was measured by employing the MTT assay with key component 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra zolium bromide (MTT) according to the manufacturer's manual (Sigma Aldrich). DNA synthesis : DNA synthesis was measured as the amount of [3H] TdR incorporated into trichloroacetic acid-precipitable material, as described elsewhere [25] . Methyl-[3H]-thymidine was from New England Nuclear (Milan, Italy).
Cell count : after 48 h of transient transfection cells were trypsinized, stained with Trypan blue and counted.
Video time lapse imaging
To determine the impact of MARCKS expression on cell cycle, time lapse microscopy was employed that enables tracking of cell cycle progression at the single cell level [17] Video microscopy was performed by culturing cells in a micro-incubator (Pecon) with controlled humidity, temperature and CO 2 , mounted on inverted Leica AM6000 microscope with fully motorized stage. ShRNA MARCKS-depleted CT26 cells and scrambled control cells were followed over 24 h. Experiments were performed acquiring multiple fields of view for each experimental condition by using oblique illumination and a 20X air objective. Multi-field acquisition was done using Leica LasAF software. Image analysis was performed by Image J software and Adobe PhotoShop.
Duration time of mitosis (DTM): mitotic entry was scored by the first image showing extensive cell rounding and is defined as the time (start t0), whereas mitotic exit was scored as the last image showing the pinching-off of the two daughter cells [17, [26] [27] [28] . The duration time of mitosis was measured for each mitotic cell in both conditions thus calculating the total sum of the DTM and the average DTM. Error bars represent standard error. The obtained average DTM of scrambled control cells (marked as t) was used as a cut-off value and compared with the DTM in MARCKS-depleted cells (marked as >t).
Statistical analysis
The statistical differences were determined by unpaired two-tailed Student's t test. Two groups were considered statistically significant when P value was less than 0.05 or 0.005 as mentioned in the figure legends. 
Results
The expression profile of MARCKS and AURKB in human colon carcinoma cell lines and in surgical specimens
In a first set of experiments, mRNA and protein expression of MARCKS were investigated in two different human colorectal carcinoma cell lines by employin g QRT-PCR and Western blot, respectively. Clone A cells were originally isolated from a poorly differentiate d human colon adenocarcinoma, whereas LoVo cells are defined as a DNA mismatch repair (MMR) deficient cell line, expressing a frameshift mutation for MARCKS inducing a truncated protein [9, 10] .
MARCKS mRNA expression in LoVo cells was detectable but at an extreme low level (<0.001 arbitrary units) when compare d to MARCKS mRNA expression in Clone A cells (Fig. 1A ). Analysing the protein expression level of MARCKS in both cell lines revealed that LoVo cells do not express MARCKS protein, whereas MARCKS was abundantly present in Clone A cells (Fig. 1B) .
These in vitro findings suggest that MARCKS expression could be characterized by high variabilit y in different colorectal carcinom as. This was also suggested by evidence obtained by investigatin g mRNA expression of MARCKS and AURKB in surgical samples of human colon carcinoma. A total of five paired samples from individual cases of CRC were investigated . Three of these samples were from patients classified in Stage I (T2, N0, MX) while two samples were from patients classified in Stage IV (TX, NX, M1) based on their case ID reported by OriGene Technologie s. As shown in Fig. 1C , the mRNA expression level of MARCKS was strongly upregulated in tumour vs normal tissue in one sample classified Stage I while no differenc e was observed in the resulting two samples.
MARCKS expression showed to be up-regulate d in one sample classified in Stage IV tumour vs normal liver tissue, whereas MARCKS expression level did not varied between tumour and normal tissue in one sample. Aurora kinase B mRNA expression was up-regulated in tumour vs normal tissue in all Stage I samples (Fig. 1D) . In two samples classified in Stage IV, AURKB expression showed to significantly be up-regulated only in one out of two cases.
Loss of function of MARCKS interferes with cell motility and invasion in Clone A cells
In this group of experiments we investigated whether changing MARCKS protein expression, and therefore the actin cytoskeleton , could affect cell migration and invasion of Clone A cells when conditioned medium of activated hHSC (hHSC-CM) was used as chemoattractan t [20] [21] [22] . Therefore, RNAi against MARCKS was performed , followed by modified Boyden chamber migration-and invasion assays. As shown in Fig. 2A , cell motility of scrambled control cells was induced by hHSC-CM, whereas migration of MARCKS-depleted cells was significantly reduced.
A similar pattern of invasion was obtained when MARCKSdepleted Clone A cells were challenged to invade a modified Boyden chamber coated with Matrigel. Invasion of scrambled control cells was induced by hHSC-CM, whereas it was strongly inhibited in MARCKS-depleted cells (Fig. 2B) .
The observed inhibition in chemotaxis towards hHSC-CM, known to be a strong hepatic chemoattractant [20] [21] [22] , coincides with evident morphological changes. Scrambled control cells showed a more epithelial phenotype, whereas MARCKS-depleted Clone A cells were characterized by mesenchymal-like features (Fig. 2C) . 
The actin binding potential of MARCKS limits migration of LoVo cells
Next we investiga ted whether cell motility was affected by reexpressing MARCKS in LoVo cells which do not normally express MARCKS protein. LoVo cells were transfected with a wild type (WT) MARCKS plasmid and two different MARCKS cDNA harbouring mutations i.e. a myristoylated mutant (Myr-m) and a deleted mutant of the PSD (PSD-m). As shown in Fig. 3A and B, MARCKS mRNA and protein expression were detectable in all three different cDNA transfected cellular conditions but not in parental empty vector transfected cells. In addition, phosphoryla ted MARCKS was detectable in WT and Myr-m transfected cells, whereas the PSDm transfected cells were negative for phosphoryla ted MARCKS, confirming that the phospho rylation site domain of MARCKS is mutated (Fig. 3B) .
Migration of LoVo cells transfected with WT MARCKS and mutated variants revealed a remarkabl e reduction in cell motility (Fig. 3A) . These findings indicate that the re-express ion of MARCKS in LoVo cells affects the actin cytoskeleton reorganizati on during migration and that both the phosphorylatio n and the myristoyl ation of MARCKS are of equal importance for MARCKS proper cycling between the cytosol and the plasma membrane in order to regulate cell motility. Interestingl y, LoVo cells that migrated towards hHSC-CM changed morphology when MARCKS expression was re-expressed. Empty vector-transfected cells showed mesenchymal-like features whereas LoVo cells transient transfected with MARCKS cDNA WT featured an epithelial phenotype (Fig. 3C) . The re-express ion of MARCKS and cDNA mutants resulted in an even higher inhibitory effect on the invasive capacity of LoVo cells. Empty vector transfected control cells invaded the Matrigel-co ated filter, whereas all transfected LoVo cells did not invade (Fig. 3D) . Overall, these data demonstrat e that MARCKS acts as a key regulator of cell motility.
MARCKS affects AURKB expression in Clone A cells and LoVo cells
In a previous study we demonstrated that MARCKS is important for proper mitosis and that RNAi against MARCKS results in a prolonged cell cycle and AURKB delocalization [17] . In this study the effect of changing MARCKS protein expression on proliferation was analysed. Moreove r, a possible link between MARCKS and AURKB in Clone A and LoVo cells was investigated .
RNAi against MARCKS expression in Clone A cells and reexpression in LoVo cells inhibited cell prolifera tion (Fig. 4A) . The inhibitory effect of changing MARCKS expression on cell proliferation coincided with a down-regul ation of AURKB protein expression in both cells lines as shown in Fig. 4B . Next, in two independen t experiments, Clone A and LoVo cells were silenced against AURKB and western blot analysis showed that MARCKS protein expression was not affected when Clone A cells were silenced against AURKB (Fig. 4C ). This finding suggests that an actin filament binding protein such as MARCKS can affect AURKB protein synthesis , but AURKB does not reciprocally affect MARCKS protein expression. 
Down-regulation of MARCKS in CT26 cells inhibits migration and invasion in vitro
The effect of MARCKS-depleti on was assessed in the murine CT26 colon carcinoma cell line in a group of in vitro experiments instrumenta l for setting an in vivo model of liver metastasiza tion. As shown in Fig. 5A , CT26 cells were stable shRNA transfected against MARCKS and cell migration and invasion were investigated. Stable shRNA MARCKS-depleted cells showed a decrease in cell motility in comparison to shRNA scrambled control cells towards mHSC-CM (Fig. 5B) . As shown in Fig. 5C , cellular invasion of shRNA-trea ted MARCKS cells was reduced in comparison to scrambled control cells when mHSC-CM was used as chemoat tractant.
MARCKS depletion delays duration time of mitosis in CT26 cells
Previous experimental evidence provided by our group suggested a key role of MARCKS in regulating the actin cytoskeleton during cell cycle in primary hHSC [17] . In this set of experiments the different phases of cell division of MARCKS-de pleted CT26 cells and shRNA scrambled control cells were monitored by obliqueillumination video time lapse-imaging and this to investigate the role of MARCKS during mitosis in neoplastic cells such as CT26 cells. More specifically, the duration time of mitosis (DTM) of each mitotic cell was measured. Stably MARCKS-de pleted CT26 cells showed a clear difference in phenotype during interphase in comparison to the scrambled shRNA control cells. These cells showed the typical epithelial phenotype whereas shRNA MARCKS-depleted cells showed a mesenchymal-l ike phenotype (Fig. 6A) . ShRNA-MARCKS-de pleted cells were inhibited in proliferation when measured by employin g MTT assay (Fig. 6B) . Next, scrambled control cells showed an average DTM of 160 min (n = 54, Fig. 6C and Supplementary Video 6.1 ), whereas mitotic shRNA MARCKS-de pleted cells are characterized by a significant increase in DTM when compared to scrambled control cells (n = 43, Fig. 6D and Supplementary Video 6.2 ). These data demonstrat e that more than 51.2% of this cell population is characterized by a marked increase in DTM when compared with the average DTM of scrambled control cells (Fig. 6E ). This feature coincided with an aberrant formation of the cleavage furrow followed by a delay in cleavage furrow ingression and pinching-of f of the two daughter cells (Supplement ary Video 6.2 and 6.3 ). In parallel, MARCKS protein expression was analysed by Western blot analysis (Fig. 6F) .
Down-regula tion of endogenou s MARCKS in CT26 cells antagonizes the metastati c ability in vivo
A CT26 murine colorectal liver metastas is assay, syngenei c to BALB/c mice, was performed in vivo to compare tumour formatio n between CT26 scrambled control cells and MARCKS-sh RNA treated cells. Stable shRNA-tran sfected CT26 cells were used in these experiments and western blot analysis showed a strong reduction in MARCKS protein expression as shown in Fig. 7A . When mice were tumour-challe nged, the suppression of MARCKS protein significantly decreased metastati c burden compared to the CT26-tumour challenged mice (Fig. 7B) . Liver metastas is in CT26 tumour-chal lenged mice demonst rated to contain 5-15 multiple macroscopic nodules occurring in a single liver (Fig. 7C) . In contrast, few or no metastas es were found macroscopicall y on the surface of the liver of those mice that were tumour-chal lenged with CT26 shRNA-depl eted of MARCKS (Fig. 7B) . This was confirmed by histology examination of performi ng haematoxyl ineosin stained sections (Fig. 7D) . In contrast to the liver, tumour formation was found at the primary site of injection , i.e. spleen, in both conditions under investiga tion (Fig. 7B) . These data confirm the previousl y observed inhibitory effect of MARCKS depletion on cell migration and invasion in vitro.
Discussions
MARCKS, a major PKC substrate, has been shown to be involved in the tumourig enesis of pituitary and thyroid tumours, breast cancer, cholangioca rcinoma and in glioblastom a multiforme. Alterations in the PKC-MARCKS-actin axis have been shown to affect processes such as motility, proliferation, invasion, adhesion, cell spreadin g and membran e trafficking [3, 7, 8, 29 ] . Moreover, recent studies have identified MARCKS as a frequent target of mutation in colorectal carcinom as and small intestinal adenocarcinom as with MSI-H [9] [10] [11] . Overall the fine molecular mechanism s through which MARCKS affects tumour progression during CRC developmen t are largely unknown.
The reorganizati on of the actin cytoskeleton is defined as the primary mechanism of cell motion during migration and cell invasion that is orchestrated by actin filament binding proteins such as MARCKS [1, 2] . In a previous study we have demonst rated the key role of MARCKS in the modulation of platelet-derive d growth factor (PDGF)-induced hHSC motility [23] . These cells are liver-specific multifunctional mesenchym al cells known to play a key role in human liver pathophysiol ogy [30] [31] [32] , including a distinct stromal contribution to the developmen t to primary and metastatic liver cancers [20] [21] [22] . In the present investigatio n we demonstrat e that colon cancer cell motility and invasion in response to an established stromal extracellular stimulus, i.e. HSC-CM, are strongly affected by modulating MARCKS expression. Indeed, by altering intracellul ar MARCKS expression and therefore actin cytoskeleton dynamics , the effect of HSC-CM was abolished in both human and murine colorectal carcinom a cell lines. These changes are related to modifications of the fine-tuned balance between actin and MARCKS regulating reversibl e and local protein-mem brane interactio ns ensuring cell plasticity, polarity and surface charge [33] [34] [35] in response to extracellular stimuli. Exogenous overexpression of MARCKS and mutational gain-on experiments revealed that MARCKS is an important determinant of cell motility and that the myristoylated domain and the phospho rylation site domain of MARCKS are of equal importance to re-organize the membrane actin cytoskeleton during migration.
In addition to colon cancer cell motility and invasion, MARCKS expression may have also relevant implication on the cell cycle, as suggested by several studies [5, 36, 37] . Since mitosis is characterized by a dynamic remodelling of the cortical actin network [38, 39] , the relationshi p between MARCKS, a key factor in actin reorganizati on, and AURBK, an important key mitotic checkpoint [15, 40] , was further investigated. Changes in MARCKS protein expression, and thus the actin cytoskeleton , led to modifications in AURBK expression as shown by gain-on and gain-off experiments in both Clone A cells and LoVo cells. These data suggest that the re-organ ization of the actin cytoskeleton has a major impact on mitotic regulators such as AURKB, in agreement with recent data from our group [17] .
The relationship between MARCKS expression and colon cancer cell biology was further confirmed in CT26 murine colon carcinoma cells in experiments preparator y to the establishment of the syngeneic in vivo model. Depletion of MARCKS resulted in reduced cell motion and prolonged cell cycle time suggesting a possible inhibitory effect on tumour growth at the metastatic site. Indeed, mice tumour-chal lenged with control cells developed a larger number of liver metastases when compared with mice tumourchallenged with MARCKS-de pleted cells thus confirming that MARCKS affects tumour progression in vivo. Altogether, the in vitro and in vivo observations obtained by MARCKS-depleti on in CT26, may recapitulate the clinical-pathol ogical characterist ics of MSI-H CRC, a CRC subtype which is characterized by unique molecular features and has distinct and relatively unknown mechanisms by which colorectal cancer arise [41] . MARCKS activity has been shown to be impaired in MSI-H CRC as a consequence of a frameshift mutation and, although MSI-H CRC are poorly differentiated, they tend to be associated with a better patient survival prognosis [42] also in reason of a significantly lower rate of distant metastas es [43] . An additional or alternative MARCKS-related mechanis m explaining the reduced incidence of metastasis in this type of CRC is the immune reaction elicited by the secretion of a frameshift-m utated protein conseque nt to the mutation of MARCKS and recognized as an antigen characterized by a high immunog enic potential [9, 44, 45] .
Taken together, the results of the present study delineate a complex and articulated role of MARCKS in the progression of colorectal cancer. MARCKS supports colon cancer cell motility, invasion and proliferation whereas lack of MARCKS markedly affects these cancer features and reduces metastasizatio n. Consequentl y, MARCKS might represent a suitable target to interfere and overcome the invasive behaviour of colon carcinoma cells at primary and distant sites. The authors declare that they have no competin g financial interests. 
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